Folinic acid ( DrugBank: Folinic acid )
3 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 46 | 悪性関節リウマチ | 3 |
| 107 | 若年性特発性関節炎 | 1 |
| 320 | 先天性グリコシルホスファチジルイノシトール（GPI）欠損症 | 2 |
46. 悪性関節リウマチ
臨床試験数 : 4,325 / 薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02379091 (ClinicalTrials.gov) | December 17, 2014 | 28/11/2014 | Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA) | A 24-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study to Evaluate the Efficacy and Safety of 3 Doses of Namilumab (20 mg, 80 mg and 150 mg) in Combination With Methotrexate (MTX) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) | Rheumatoid Arthritis | Drug: Namilumab;Drug: Placebo;Drug: Methotrexate;Drug: Folic/folinic acid | Takeda | NULL | Completed | 18 Years | N/A | All | 108 | Phase 2 | Bulgaria;Czechia;Japan;Korea, Republic of;Poland;Russian Federation;Spain;United Kingdom;Argentina;Brazil;Colombia;Czech Republic;Germany;Mexico |
| 2 | NCT01217814 (ClinicalTrials.gov) | November 2010 | 7/10/2010 | Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-a Blockers | A Randomized, Double-blind, Parallel-group, Placebo- and Active Calibrator-controlled Study Assessing the Clinical Benefit of SAR153191 Subcutaneous (SC) on Top of MTX in Patients With Active RA Who Have Failed Previous TNF-a Antagonists | Rheumatoid Arthritis | Drug: Sarilumab;Drug: Placebo;Drug: Golimumab;Drug: methotrexate (MTX);Drug: Folic/folinic acid | Sanofi | Regeneron Pharmaceuticals | Terminated | 18 Years | 75 Years | All | 16 | Phase 2 | United States;Colombia;Czechia;Italy;Mexico;Spain;Brazil;Canada;Czech Republic;Germany;Hungary;Norway |
| 3 | NCT00000395 (ClinicalTrials.gov) | September 1996 | 3/11/1999 | Antifolate Effectiveness in Arthritis | Mechanisms of Antifolate Efficacy in Arthritis | Rheumatoid Arthritis;Adjuvant Arthritis | Drug: Methotrexate;Dietary Supplement: Folinic acid;Dietary Supplement: Folic acid | University of Alabama at Birmingham | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);Office of Dietary Supplements (ODS) | Completed | 18 Years | 85 Years | Both | 40 | Phase 2 | United States |
107. 若年性特発性関節炎
臨床試験数 : 441 / 薬物数 : 282 - (DrugBank : 56) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04169828 (ClinicalTrials.gov) | August 2, 2019 | 18/11/2019 | The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis | The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis | Juvenile Idiopathic Arthritis | Drug: Methotrexate;Drug: Ondansetron;Drug: Folic/folinic acid | University of British Columbia | The Arthritis Society, Canada;University of Calgary;IWK Health Centre;The Hospital for Sick Children;McGill University Health Centre/Research Institute of the McGill University Health Centre;London Health Sciences Centre;University of Manitoba;Children's Hospital of Eastern Ontario;Alberta Children's Hospital;McMaster University;McMaster Children's Hospital;Université de Montréal;Royal University Hospital Foundation;Memorial University of Newfoundland | Recruiting | 4 Years | 16 Years | All | 176 | N/A | Canada |
320. 先天性グリコシルホスファチジルイノシトール（GPI）欠損症
臨床試験数 : 3 / 薬物数 : 2 - (DrugBank : 2) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCTs051180113 | 01/04/2019 | 11/03/2019 | Novel replacement therapy for inherited GPI deficiency | Novel replacement therapy for inherited GPI deficiency - Novel replacement therapy for inherited GPI deficiency | Inherited GPI deficiency Inherited GPI deficiency | Folinic acid 1mg/kg/day in three divided dose to start. If the 5-MTHF concentration in cerebrospinal fluid will be low after one month, folinic acid will be uo to 2-5mg/kg/day.The period of administration is six months in principle. | Nabatame Shin | NULL | Recruiting | Not applicable | Not applicable | Both | 5 | N/A | Japan |
| 2 | JPRN-UMIN000030314 | 2019/04/01 | 15/01/2018 | Novel replacement therapy for inherited GPI deficiency (IGD) | Novel replacement therapy for inherited GPI deficiency (IGD) - Novel replacement therapy for inherited GPI deficiency (IGD) | Inherited GPI deficiency | Folinic acid 1mg/kg/day in three divided dose to start. If the 5-MTHF concentration in cerebrospinal fluid will be low after one month, folinic acid will be uo to 2-5mg/kg/day.The period of administration is six months in principle. | Osaka University | NULL | Recruiting | Not applicable | Not applicable | Male and Female | 5 | Not selected | Japan |